Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?
Exelixis, Inc. (NASDAQ:EXEL) disclosed in a September 11 filing that the FDA had extended the review of zanzalintinib by three months, setting a new target action date of March 3, 2027.







